Last reviewed · How we verify
Ioxaglate
At a glance
| Generic name | Ioxaglate |
|---|---|
| Also known as | Hexabrix |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Imaging Study of 3D-CBCT Sialography and MRI Sialography in Non Tumor Salivary Diseases
- Ioxaglate Versus Iodixanol for the Prevention of Contrast-induced Nephropathy in High-risk Patients (IDPC Trial)
- Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography (PHASE4)
- Preventing Contrast-induced Nephropathy: Evaluating Hydration Strategies and L-carnitine Administration (PHASE3)
- RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ioxaglate CI brief — competitive landscape report
- Ioxaglate updates RSS · CI watch RSS
- NYU Langone Health portfolio CI